



cancers



an Open Access Journal by MDPI

Therapeutic Approaches for Myeloproliferative Neoplasms

Guest Editors:

Dr. Massimo Breccia

Department of Translational and
Precision Medicine, Sapienza
University of Rome, Rome, Italy

Dr. Francesca Palandri

Istituto di Ematologia
“Seràgnoli”, IRCCS Azienda
Ospedaliero-Universitaria di
Bologna, Bologna, Italy

Deadline for manuscript
submissions:

closed (30 April 2024)

Message from the Guest Editors

Dear Colleagues,

Myeloproliferative neoplasms (MPNs) are clonal hematopoietic stem cell myeloid neoplasms that are characterized by the proliferation and preserved differentiation of myeloid cell lineages. Excluding *BCR-ABL1*-positive chronic myeloid leukemia (CML), essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (PMF) are the most frequent MPNs.

Constitutive activation of the Janus kinase 2 (JAK2)/signal transducer and activator of transcription (STAT) signaling pathway due to acquired somatic mutations in the *JAK2*, *calreticulin* or *MPL* genes may drive the course of MPNs.

Traditional treatment approaches for PV and ET focus on the prevention of thrombotic events with aspirin along with antiproliferative agents. Treatment strategies for MF are driven by clinical presentations such as anemia and/or splenomegaly.

In this Special Issue, we aim to collect studies and reviews about the therapeutic landscape of MPNs, with a particular focus on new treatments.



mdpi.com/si/176189

Special Issue



cancers



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (*Oncology*) / CiteScore - Q1 (*Oncology*)

Contact Us

Cancers Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
X@Cancers_MDPI